| Title | Trust Me, I'm a Chatbot: How Artificial Intelligence in Health Care Fails the Turing Test. |
| Authors | Powell, J |
| Journal | Journal of medical Internet research |
| Publication Date | 28 Oct 2019 |
| Date Added to PubMed | 30 Oct 2019 |
| Abstract | Over the next decade, one issue which will dominate sociotechnical studies in health informatics is the extent to which the promise of artificial intelligence in health care will be realized, along with the social and ethical issues which accompany it. A useful thought experiment is the application of the Turing test to user-facing artificial intelligence systems in health care (such as chatbots or conversational agents). In this paper I argue that many medical decisions require value judgements and the doctor-patient relationship requires empathy and understanding to arrive at a shared decision, often handling large areas of uncertainty and balancing competing risks. Arguably, medicine requires wisdom more than intelligence, artificial or otherwise. Artificial intelligence therefore needs to supplement rather than replace medical professionals, and identifying the complementary positioning of artificial intelligence in medical consultation is a key challenge for the future. In health care, artificial intelligence needs to pass the implementation game, not the imitation game. |
| Link | http://doi.org/10.2196/16222 |
| Title | An artificial intelligence-based first-line defence against COVID-19: digitally screening citizens for risks via a chatbot. |
| Authors | Martin, A; Nateqi, J; Gruarin, S; Munsch, N; Abdarahmane, I; Zobel, M; Knapp, B |
| Journal | Scientific reports |
| Publication Date | 4 Nov 2020 |
| Date Added to PubMed | 6 Nov 2020 |
| Abstract | To combat the pandemic of the coronavirus disease 2019 (COVID-19), numerous governments have established phone hotlines to prescreen potential cases. These hotlines have struggled with the volume of callers, leading to wait times of hours or, even, an inability to contact health authorities. Symptoma is a symptom-to-disease digital health assistant that can differentiate more than 20,000 diseases with an accuracy of more than 90%. We tested the accuracy of Symptoma to identify COVID-19 using a set of diverse clinical cases combined with case reports of COVID-19. We showed that Symptoma can accurately distinguish COVID-19 in 96.32% of clinical cases. When considering only COVID-19 symptoms and risk factors, Symptoma identified 100% of those infected when presented with only three signs. Lastly, we showed that Symptoma's accuracy far exceeds that of simple "yes-no" questionnaires widely available online. In summary, Symptoma provides unparalleled accuracy in systematically identifying cases of COVID-19 while also considering over 20,000 other diseases. Furthermore, Symptoma allows free text input, furthered with disease-specific follow up questions, in 36 languages. Combined, these results and accessibility give Symptoma the potential to be a key tool in the global fight against COVID-19. The Symptoma predictor is freely available online at https://www.symptoma.com . |
| Link | http://doi.org/10.1038/s41598-020-75912-x |
| Title | Preliminary Evaluation of a mHealth Coaching Conversational Artificial Intelligence for the Self-Care Management of People with Sickle-Cell Disease. |
| Authors | Issom, DZ; Rochat, J; Hartvigsen, G; Lovis, C |
| Journal | Studies in health technology and informatics |
| Publication Date | 16 Jun 2020 |
| Date Added to PubMed | 24 Jun 2020 |
| Abstract | Adherence to the complex set of recommended self-care practices among people with Sickle-Cell Disease (SCD) positively impacts health outcomes. However, few patients possess the required skills (i.e. disease-specific knowledge, adequate levels of self-efficacy). Consequently, adherence rates remain low and only 1% of patients are empowered enough to master the self-care practices. Health coaching and therapeutic patient education have emerged as new approaches to enhance patients' self-management and support health behavior changes. This preliminary feasibility study examined patients' perceived usefulness of the information provided by a chatbot we developed following patient-important requirements collected during our preliminary studies. Participants tested the chatbot and completed a post-test survey. A total of 19 patients were enrolled and 2 withdrew. 15 respondents (15/17, 88%) gave a score of at least 3/4 to the question "The chatbot contains all the information I need". Results suggest that mHealth coaching apps could be used to promote the knowledge acquisition of recommended health behaviors related to the prevention of SCD main symptoms. |
| Link | http://doi.org/10.3233/SHTI200442 |
| Title | Assessing the feasibility of a chatbot after ureteroscopy. |
| Authors | Goldenthal, SB; Portney, D; Steppe, E; Ghani, K; Ellimoottil, C |
| Journal | mHealth |
| Publication Date | 1 Dec 2019 |
| Date Added to PubMed | 26 Apr 2019 |
| Abstract | Patients experience common symptoms and/or complications after undergoing ureteroscopy, which is a common procedure used to treat kidney stones. Current methods for patient education regarding these complications include counseling and discharge materials. This study aimed to assess chatbot usage and their ability to deliver information to patient post-ureteroscopy. Patients who underwent ureteroscopy at the University of Michigan were given instructions to activate the chatbot. Within one to four weeks of their surgery, semi-structured interviews were conducted regarding post-surgical recovery and chatbot usage. Twenty patients were interviewed, seven of whom activated the chatbot. Frequent reasons for not activating the chatbot included misplacing instructions for chatbot use (n=6), relying on follow-up with clinic or discharge materials (n=4), inability to activate chatbot (n=2), and inability to text (n=1). Perceived benefits included alleviation of concerns surrounding common symptoms and quick access to information for non-emergent issues. These results suggest that chatbots are a convenient method to address common concerns post-ureteroscopy. However, better integration in the flow of care delivery and improved usability are needed to increase patient engagement. |
| Link | http://doi.org/10.21037/mhealth.2019.03.01 |
| Title | Clinical Integration of Digital Solutions in Health Care: An Overview of the Current Landscape of Digital Technologies in Cancer Care. |
| Authors | Garg, S; Williams, NL; Ip, A; Dicker, AP |
| Journal | JCO clinical cancer informatics |
| Publication Date | 1 Dec 2018 |
| Date Added to PubMed | 18 Jan 2019 |
| Abstract | Digital health constitutes a merger of both software and hardware technology with health care delivery and management, and encompasses a number of domains, from wearable devices to artificial intelligence, each associated with widely disparate interaction and data collection models. In this review, we focus on the landscape of the current integration of digital health technology in cancer care by subdividing digital health technologies into the following sections: connected devices, digital patient information collection, telehealth, and digital assistants. In these sections, we give an overview of the potential clinical impact of such technologies as they pertain to key domains, including patient education, patient outcomes, quality of life, and health care value. We performed a search of PubMed ( www.ncbi.nlm.nih.gov/pubmed ) and www.ClinicalTrials.gov for numerous terms related to digital health technologies, including digital health, connected devices, smart devices, wearables, activity trackers, connected sensors, remote monitoring, electronic surveys, electronic patient-reported outcomes, telehealth, telemedicine, artificial intelligence, chatbot, and digital assistants. The terms health care and cancer were appended to the previously mentioned terms to filter results for cancer-specific applications. From these results, studies were included that exemplified use of the various domains of digital health technologies in oncologic care. Digital health encompasses the integration of a vast array of technologies with health care, each associated with varied methods of data collection and information flow. Integration of these technologies into clinical practice has seen applications throughout the spectrum of care, including cancer screening, on-treatment patient management, acute post-treatment follow-up, and survivorship. Implementation of these systems may serve to reduce costs and workflow inefficiencies, as well as to improve overall health care value, patient outcomes, and quality of life. |
| Link | http://doi.org/10.1200/CCI.17.00159 |
| Title | Does the addition of a supportive chatbot promote user engagement with a smoking cessation app? An experimental study. |
| Authors | Perski, O; Crane, D; Beard, E; Brown, J |
| Journal | Digital health |
| Publication Date | 1 Dec |
| Date Added to PubMed | 18 Oct 2019 |
| Abstract | The objective of this study was to assess whether a version of the Smoke Free app with a supportive chatbot powered by artificial intelligence (versus a version without the chatbot) led to increased engagement and short-term quit success. Daily or non-daily smokers aged ≥18 years who purchased the 'pro' version of the app and set a quit date were randomly assigned (unequal allocation) to receive the app with or without the chatbot. The outcomes were engagement (i.e. total number of logins over the study period) and self-reported abstinence at a one-month follow-up. Unadjusted and adjusted negative binomial and logistic regression models were fitted to estimate incidence rate ratios (IRRs) and odds ratios (ORs) for the associations of interest. A total of 57,214 smokers were included (intervention: 9.3% (5339); control: 90.7% (51,875). The app with the chatbot compared with the standard version led to a 101% increase in engagement (IRRadj = 2.01, 95% confidence interval (CI) = 1.92-2.11, p < .001). The one-month follow-up rate was 10.6% (intervention: 19.9% (1,061/5,339); control: 9.7% (5,050/51,875). Smokers allocated to the intervention had greater odds of quit success (missing equals smoking: 844/5,339 vs. 3,704/51,875, ORadj = 2.38, 95% CI = 2.19-2.58, p < .001; follow-up only: 844/1,061 vs. 3,704/5,050, ORadj = 1.36, 95% CI = 1.16-1.61, p < .001). The addition of a supportive chatbot to a popular smoking cessation app more than doubled user engagement. In view of very low follow-up rates, there is low quality evidence that the addition also increased self-reported smoking cessation. |
| Link | http://doi.org/10.1177/2055207619880676 |
| Title | Use of the Chatbot "Vivibot" to Deliver Positive Psychology Skills and Promote Well-Being Among Young People After Cancer Treatment: Randomized Controlled Feasibility Trial. |
| Authors | Greer, S; Ramo, D; Chang, YJ; Fu, M; Moskowitz, J; Haritatos, J |
| Journal | JMIR mHealth and uHealth |
| Publication Date | 31 Oct 2019 |
| Date Added to PubMed | 2 Nov 2019 |
| Abstract | Positive psychology interventions show promise for reducing psychosocial distress associated with health adversity and have the potential to be widely disseminated to young adults through technology. This pilot randomized controlled trial examined the feasibility of delivering positive psychology skills via the Vivibot chatbot and its effects on key psychosocial well-being outcomes in young adults treated for cancer. Young adults (age 18-29 years) were recruited within 5 years of completing active cancer treatment by using the Vivibot chatbot on Facebook messenger. Participants were randomized to either immediate access to Vivibot content (experimental group) or access to only daily emotion ratings and access to full chatbot content after 4 weeks (control). Created using a human-centered design process with young adults treated for cancer, Vivibot content includes 4 weeks of positive psychology skills, daily emotion ratings, video, and other material produced by survivors, and periodic feedback check-ins. All participants were assessed for psychosocial well-being via online surveys at baseline and weeks 2, 4, and 8. Analyses examined chatbot engagement and open-ended feedback on likability and perceived helpfulness and compared experimental and control groups with regard to anxiety and depression symptoms and positive and negative emotion changes between baseline and 4 weeks. To verify the main effects, follow-up analyses compared changes in the main outcomes between 4 and 8 weeks in the control group once participants had access to all chatbot content. Data from 45 young adults (36 women; mean age: 25 [SD 2.9]; experimental group: n=25; control group: n=20) were analyzed. Participants in the experimental group spent an average of 74 minutes across an average of 12 active sessions chatting with Vivibot and rated their experience as helpful (mean 2.0/3, SD 0.72) and would recommend it to a friend (mean 6.9/10; SD 2.6). Open-ended feedback noted its nonjudgmental nature as a particular benefit of the chatbot. After 4 weeks, participants in the experimental group reported an average reduction in anxiety of 2.58 standardized t-score units, while the control group reported an increase in anxiety of 0.7 units. A mixed-effects models revealed a trend-level (P=.09) interaction between group and time, with an effect size of 0.41. Those in the experimental group also experienced greater reductions in anxiety when they engaged in more sessions (z=-1.9, P=.06). There were no significant (or trend level) effects by group on changes in depression, positive emotion, or negative emotion. The chatbot format provides a useful and acceptable way of delivering positive psychology skills to young adults who have undergone cancer treatment and supports anxiety reduction. Further analysis with a larger sample size is required to confirm this pattern. |
| Link | http://doi.org/10.2196/15018 |
| Title | Introducing Edna: A trainee chatbot designed to support communication about additional (secondary) genomic findings. |
| Authors | Ireland, D; Bradford, D; Szepe, E; Lynch, E; Martyn, M; Hansen, D; Gaff, C |
| Journal | Patient education and counseling |
| Publication Date | 10 Nov 2020 |
| Date Added to PubMed | 26 Nov 2020 |
| Abstract | To support informed decision-making about reanalysis of clinical genomic data for risk of preventable conditions ('additional findings') by developing a chatbot (electronic genetic resource, 'eDNA'). Interactions in pre-test genetic counseling sessions (13.5 h) about additional findings were characterized using proponent, thematic and semantic analyses of transcripts. We then wrote interfaces to draw supplementary data from external genetics applications. To create Edna, this content was programmed using a chatbot framework which interacts with patients via speech-to-text. Conditions, terms, explanations of concepts, and key factors to consider in decision making were all encoded into chatbot conversations emulating counseling session flows. Patient agency can be enhanced by prompted consideration of the personal and familial implications of testing. Similarly, health literacy can be broadened through explanation of genetic conditions and terminology. Novel aspects include sentiment analysis and collection of family history. Medical advice and the impact of existing genetic conditions were deemed inappropriate for inclusion. Edna's successful development represents a movement towards accessible, acceptable and well-supported digital health processes for patients to make informed decisions for additional findings. Edna complements genetic counseling by collecting and providing genomic information before or after pre-test consultations. |
| Link | http://doi.org/10.1016/j.pec.2020.11.007 |
| Title | Physicians' Perceptions of the Use of a Chatbot for Information Seeking: Qualitative Study. |
| Authors | Koman, J; Fauvelle, K; Schuck, S; Texier, N; Mebarki, A |
| Journal | Journal of medical Internet research |
| Publication Date | 10 Nov 2020 |
| Date Added to PubMed | 11 Nov 2020 |
| Abstract | Seeking medical information can be an issue for physicians. In the specific context of medical practice, chatbots are hypothesized to present additional value for providing information quickly, particularly as far as drug risk minimization measures are concerned. This qualitative study aimed to elicit physicians' perceptions of a pilot version of a chatbot used in the context of drug information and risk minimization measures. General practitioners and specialists were recruited across France to participate in individual semistructured interviews. Interviews were recorded, transcribed, and analyzed using a horizontal thematic analysis approach. Eight general practitioners and 2 specialists participated. The tone and ergonomics of the pilot version were appreciated by physicians. However, all participants emphasized the importance of getting exhaustive, trustworthy answers when interacting with a chatbot. The chatbot was perceived as a useful and innovative tool that could easily be integrated into routine medical practice and could help health professionals when seeking information on drug and risk minimization measures. |
| Link | http://doi.org/10.2196/15185 |
| Title | A Smartphone-Based Health Care Chatbot to Promote Self-Management of Chronic Pain (SELMA): Pilot Randomized Controlled Trial. |
| Authors | Hauser-Ulrich, S; Künzli, H; Meier-Peterhans, D; Kowatsch, T |
| Journal | JMIR mHealth and uHealth |
| Publication Date | 3 Apr 2020 |
| Date Added to PubMed | 4 Apr 2020 |
| Abstract | Ongoing pain is one of the most common diseases and has major physical, psychological, social, and economic impacts. A mobile health intervention utilizing a fully automated text-based health care chatbot (TBHC) may offer an innovative way not only to deliver coping strategies and psychoeducation for pain management but also to build a working alliance between a participant and the TBHC. The objectives of this study are twofold: (1) to describe the design and implementation to promote the chatbot painSELfMAnagement (SELMA), a 2-month smartphone-based cognitive behavior therapy (CBT) TBHC intervention for pain self-management in patients with ongoing or cyclic pain, and (2) to present findings from a pilot randomized controlled trial, in which effectiveness, influence of intention to change behavior, pain duration, working alliance, acceptance, and adherence were evaluated. Participants were recruited online and in collaboration with pain experts, and were randomized to interact with SELMA for 8 weeks either every day or every other day concerning CBT-based pain management (n=59), or weekly concerning content not related to pain management (n=43). Pain-related impairment (primary outcome), general well-being, pain intensity, and the bond scale of working alliance were measured at baseline and postintervention. Intention to change behavior and pain duration were measured at baseline only, and acceptance postintervention was assessed via self-reporting instruments. Adherence was assessed via usage data. From May 2018 to August 2018, 311 adults downloaded the SELMA app, 102 of whom consented to participate and met the inclusion criteria. The average age of the women (88/102, 86.4%) and men (14/102, 13.6%) participating was 43.7 (SD 12.7) years. Baseline group comparison did not differ with respect to any demographic or clinical variable. The intervention group reported no significant change in pain-related impairment (P=.68) compared to the control group postintervention. The intention to change behavior was positively related to pain-related impairment (P=.01) and pain intensity (P=.01). Working alliance with the TBHC SELMA was comparable to that obtained in guided internet therapies with human coaches. Participants enjoyed using the app, perceiving it as useful and easy to use. Participants of the intervention group replied with an average answer ratio of 0.71 (SD 0.20) to 200 (SD 58.45) conversations initiated by SELMA. Participants' comments revealed an appreciation of the empathic and responsible interaction with the TBHC SELMA. A main criticism was that there was no option to enter free text for the patients' own comments. SELMA is feasible, as revealed mainly by positive feedback and valuable suggestions for future revisions. For example, the participants' intention to change behavior or a more homogenous sample (eg, with a specific type of chronic pain) should be considered in further tailoring of SELMA. German Clinical Trials Register DRKS00017147; https://tinyurl.com/vx6n6sx, Swiss National Clinical Trial Portal: SNCTP000002712; https://www.kofam.ch/de/studienportal/suche/70582/studie/46326. |
| Link | http://doi.org/10.2196/15806 |